Zidolam Tablet

$39.03

1 Bottle, 60 tablets per bottle

Active ingredient: Lamivudine (150mg) + Zidovudine (300mg)

Out of stock

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout

Placeholder
Zidolam Tablet
$39.03

Introduction

Zidolam is a prescription medication that combines two active ingredients: Lamivudine and Zidovudine. It is available in tablet form and is commonly prescribed for the treatment of HIV infection. Lamivudine and Zidovudine are antiretroviral medications that work by inhibiting the replication of the human immunodeficiency virus (HIV) in the body.

Uses

Zidolam is primarily used to manage HIV infection in adults and children. It is typically prescribed as part of a combination therapy regimen to reduce the viral load in the blood, improve immune function, and prevent the progression of HIV to acquired immunodeficiency syndrome (AIDS). This medication does not cure HIV infection, but it helps to control the virus and improve the quality of life for individuals living with HIV.

Dosage and Administration

The dosage of Zidolam may vary depending on the individual’s age, weight, and other factors. Follow the instructions provided by your healthcare provider. Typically, the recommended dose for adults is one tablet taken orally twice daily, with or without food. For children, the dosage is based on body weight and is determined by the prescribing healthcare professional.

Mechanism of Action

Zidolam contains two active ingredients: Lamivudine and Zidovudine. Lamivudine belongs to a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs), while Zidovudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI). Together, these medications work by blocking the reverse transcriptase enzyme, which is necessary for the replication of HIV. By inhibiting viral replication, Zidolam helps to reduce the viral load in the body and slow down the progression of HIV infection.

Side Effects

Common side effects may include headache, nausea, vomiting, diarrhea, fatigue, and dizziness. These side effects are usually mild and temporary. However, if you experience any persistent or severe side effects, contact your healthcare provider.

In rare cases, Zidolam may cause serious side effects, such as liver problems, blood disorders, or allergic reactions. If you develop symptoms such as yellowing of the skin or eyes, unusual bleeding or bruising, or signs of an allergic reaction (such as rash, itching, or swelling), seek immediate medical attention.

Drug Interactions

Zidolam may interact with other medications, herbs, or supplements. Inform your healthcare provider about all the medications you are currently taking, including over-the-counter drugs and herbal supplements. Certain medications, such as rifampin or other drugs that affect liver enzymes, may reduce the effectiveness of Zidolam. Your healthcare provider will determine the best treatment plan and adjust your medication regimen accordingly.

Precautions

Before taking Zidolam, inform your healthcare provider about any medical conditions you have, especially liver disease, kidney disease, or a history of blood disorders. This medication may not be suitable for everyone, and your healthcare provider will assess the risks and benefits before prescribing it.

Zidolam should not be used during pregnancy unless specifically directed by your healthcare provider. Use effective contraception methods while taking this medication, as it can cause harm to an unborn baby. If you are breastfeeding, consult your healthcare provider before taking Zidolam, as it may pass into breast milk.

Additionally, Zidolam may interact with certain medications or substances, such as alcohol. Avoid excessive alcohol consumption while taking this medication, as it can increase the risk of side effects and liver damage.

Storage

Zidolam should be stored at room temperature, away from excessive heat, moisture, and light. Keep the medication out of the reach of children and pets. Do not use Zidolam if the packaging is damaged or if the tablets appear discolored or deteriorated.

Patient Tips

  • Take Zidolam exactly as prescribed by your healthcare provider. Do not skip doses or stop taking the medication without medical advice.
  • If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.
  • maintain regular follow-up appointments with your healthcare provider to monitor your response to the medication and adjust the treatment plan if needed.
  • Remember to practice safe sex and use barrier methods (such as condoms) to reduce the risk of transmitting HIV to others.
  • If you have any questions or concerns about Zidolam or its use, consult your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

  • Abacavir/Lamivudine 600 mg/300 mg film-coated tablets (Health Professionals SmPC) Available at:
  • Lamivudine (Drugs.com) [Accessed 28 Jun. 2024] (online) Available at:
  • lamivudine (RX) [Accessed 28 Jun. 2024] (online) Available at:
  • Dolutegravir and Lamivudine (MedlinePlus) [Accessed 1 Jun. 2024] (online) Available at:
  • Roediger R, Smyth EK, Dieterich D. Adefovir for lamivudine-resistant hepatitis B. Antivir Ther. 2022 Apr;27(2):13596535211067605. doi: 10.1177/13596535211067605. [Accessed 9 Jun. 2024] Available at:

Additional information

Active ingredients

Strength

Lamivudine (150mg) + Zidovudine (300mg)

Dosage form

Tablet

Indications

HIV infection

Brand

Manufacturer

Manufacturer's location

7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad – 500 018. Telangana, INDIA

Reviews

There are no reviews yet.

Be the first to review “Zidolam Tablet”

Your email address will not be published. Required fields are marked *